Binge Eating Disorders Market Set to Grow Steadily Through 2035 – BIS Research

What Is Binge Eating Disorder? 

Binge eating disorder is a frequently diagnosed eating disorder characterized by recurrent episodes of consuming unusually large amounts of food with a feeling of loss of control without compensatory behaviors like purging. It carries serious risks including obesity, type 2 diabetes, cardiovascular disease, gastroesophageal reflux, sleep disturbances, and depression. 

What Is the Market Outlook? 

Therapy Adoption: 

Treatment strategies include pharmacological options (e.g. lisdexamfetamine the only FDA- and TGA‑approved drug for BED SSRIs, antidepressants, anticonvulsants), alongside psychological therapies such as cognitive behavioural therapy (CBT), and behavioral weight loss approaches. New pipeline therapies and digital health tools are emerging. 

Regional Expansion: 

The market is segmented by North America (dominant share), Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads due to higher diagnosis rates and therapy access, while Asia-Pacific is the fastest‐growing region thanks to rising awareness, mental health focus, and healthcare infrastructure expansion. 

Competitive & Clinical Focus: 

Key industry players include Takeda Pharmaceutical, Sunovion, H. Lundbeck, Novo Nordisk, Eli Lilly, Jazz Pharmaceuticals, VIVUS, and others. They are involved in both marketed products and clinical-stage therapies. Antidepressants dominate the drug class segment; online and offline pharmacy channels contribute to distribution. 

How Fast Is the Market Growing? 

The global binge eating disorders (BED) market is witnessing steady and sustained growth, supported by an increasing focus on mental health, greater awareness of BED symptoms, and improved access to therapeutic interventions. Market dynamics are shaped by a combination of rising diagnosis rates, broader acceptance of pharmacological and behavioral therapies, and ongoing research into novel treatment modalities. 

BIS Research anticipates this upward momentum will continue through the next decade, as pharmaceutical companies advance clinical trials, regulatory approvals increase, and more patients receive timely diagnosis and treatment. Expanding mental health infrastructure in emerging regions and supportive policy environments are expected to further accelerate market expansion. 

How Will This Report Help You? 

Planning to Enter the Market? 

Analyze prevalence trends across regions, understand treatment adoption patterns, and forecast demand by therapy type and distribution channel. 

Analyzing the Competitive Landscape? 

Evaluate profiles of companies developing BED treatments from stimulants and antidepressants to emerging biologics and digital therapeutics. Track recent clinical developments, approval status, and partnerships. 

Seeking R&D Insights? 

Inspect pipeline therapies including topiramate adjuncts, novel SSRIs, opioid antagonists and research into combined behavioral/pharmacological models. Explore digital innovations like mobile app support and AI-based monitoring. 

Interested in Regional Market Trends? 

Understand differing prevalence, regulatory environments, reimbursement systems, and infrastructure readiness by country and region from North America through Asia‑Pacific, Latin America, and MEA. 

Download the Full TOC or Book a Preview   

What Technologies Are Transforming the Market? 

• Approved Pharmacotherapies: Lisdexamfetamine is the only FDA/TGA-approved drug for BED; SSRIs, anticonvulsants, and stimulants are used off-label. 
• Psychological Interventions: CBT and behavioral weight loss programs demonstrate strong remission and weight outcomes, often outperforming medication alone. 
• Digital Tools & Apps: Emerging platforms (e.g. mood-tracking, self‑help apps) and wearable-assisted interventions support behavior change and adherence. 
• Combination Therapy Models: Pairing medication (e.g. topiramate) and behavioral interventions may enhance weight loss and treatment retention. 

What's Driving Demand, Opportunities & Barriers?

Demand Drivers 

• Rising prevalence of BED globally (estimated lifetime prevalence ~1%–3%; higher in women) 
• Improved diagnosis and greater awareness of mental-health implications 
• Greater adoption of pharmacotherapy and digital interventions 

Opportunities 

• Expansion into emerging markets with increasing healthcare access (e.g. Asia-Pacific, Latin America) 
• New therapy launches and pipeline products targeting BED specifically 
• Strategic collaborations, including digital health integration and behavioral applications 

Challenges 

• Side effects and limited long‑term efficacy of some medications 
• Social stigma and low awareness in certain regions limiting diagnosis rates 
• Reimbursement gaps and affordability concerns, particularly for novel or branded therapies  

Key players  

• Eli Lilly and Company 

• Amneal Pharmaceuticals, Inc. 

• Takeda Pharmaceutical, Ltd. 

• Tryp Therapeutics Inc. 

• Tonix Pharmaceuticals Corp. 

• Sumitomo Pharma Ltd. 

• VIVUS Inc 

• Novartis AG 

• Pfizer Inc. 

Strategic Developments 

• Clinical Trials & Approvals: Pipeline studies evaluating stimulants, SSRIs, anticonvulsants, and novel compounds. Recent approvals like lisdexamfetamine have shifted treatment paradigms. 
• M&A & Collaborations: Partnerships between drug developers, academic centers, and digital health firms. 
• Diagnostic Expansion: Increased screening efforts allow earlier detection and therapy initiation. 

Download the complete TOC now! 

Case Study 

Clinical data supports the idea that combining pharmacotherapy (e.g. topiramate or lisdexamfetamine) with CBT leads to higher remission rates and sustained reductions in binge episodes compared to monotherapy, based on controlled trial outcomes. 

Schedule a Call with Industry Experts  

Related Reports from BIS Research  

Activated Carbon Market for Water Treatment 

Small Modular Reactor Market 

White Biotechnology Market 

About BIS Research  

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.    

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.     

BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.    

Contact  

Head of Marketing   

Email: media@bisresearch.com     

BIS Research Inc.    

39111 PASEO PADRE PKWY STE 313,    

FREMONT, CA 94538-1686   

Visit our Blog @https://bisresearch.com/insights   

Get Expert Insights @https://community.insightmonk.com     

Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research     

Connect with us on Twitter@ https://twitter.com/BISResearch    

Connect with us on Medium@ https://medium.com/@faisal.bis  

Connect with us on YouTube@ https://www.youtube.com/@BISResearchInc